SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Biolase, Inc. – ‘S-1/A’ on 1/30/24 – ‘EX-23.1’

On:  Tuesday, 1/30/24, at 9:57pm ET   ·   As of:  1/31/24   ·   Accession #:  1193125-24-19898   ·   File #:  333-276596

Previous ‘S-1’:  ‘S-1’ on 1/19/24   ·   Next:  ‘S-1/A’ on 2/7/24   ·   Latest:  ‘S-1/A’ on 3/27/24   ·   38 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/31/24  Biolase, Inc.                     S-1/A                  9:3.2M                                   Donnelley … Solutions/FA

Pre-Effective Amendment to Registration Statement (General Form)   —   Form S-1   —   SA’33

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-1/A       Pre-Effective Amendment to Registration Statement   HTML   2.50M 
                (General Form)                                                   
 2: EX-1.3      Underwriting Agreement or Conflict Minerals Report  HTML     93K 
 3: EX-4.6      Instrument Defining the Rights of Security Holders  HTML     95K 
 4: EX-4.7      Instrument Defining the Rights of Security Holders  HTML    104K 
 5: EX-4.8      Instrument Defining the Rights of Security Holders  HTML    125K 
 6: EX-5.1      Opinion of Counsel re: Legality                     HTML     22K 
 7: EX-10.25    Material Contract                                   HTML    188K 
 8: EX-23.1     Consent of Expert or Counsel                        HTML      6K 
 9: EX-FILING FEES  Filing Fees                                     HTML     50K 


‘EX-23.1’   —   Consent of Expert or Counsel


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  EX-23.1  

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

BIOLASE, Inc.

Lake Forest, California

We hereby consent to the use in the Prospectus constituting a part of this Registration Statement of our report dated March 28, 2023, relating to the consolidated financial statements and schedule of BIOLASE, Inc. which are contained in that Prospectus. Our report on the consolidated financial statements contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.

We also consent to the reference to us under the caption “Experts” in the Prospectus.

/s/ BDO USA, P.C.

Costa Mesa, California

January 30, 2024


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘S-1/A’ Filing    Date    Other Filings
Filed as of:1/31/24
Filed on:1/30/24
3/28/2310-K,  8-K,  ARS,  DEF 14A
 List all Filings 


2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/09/24  Biolase, Inc.                     S-1/A                  4:3M                                     Donnelley … Solutions/FA
 2/07/24  Biolase, Inc.                     S-1/A                  8:3.3M                                   Donnelley … Solutions/FA


36 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/19/24  Biolase, Inc.                     S-1                    3:2.6M                                   Donnelley … Solutions/FA
12/08/23  Biolase, Inc.                     8-K:1,3,8,912/06/23   16:767K                                   Donnelley … Solutions/FA
 9/18/23  Biolase, Inc.                     8-K:1,3,5,8 9/13/23   16:887K                                   Donnelley … Solutions/FA
 8/30/23  Biolase, Inc.                     S-1/A                  8:1.3M                                   Donnelley … Solutions/FA
 6/23/23  Biolase, Inc.                     8-K:4,9     6/21/23   11:147K                                   Donnelley … Solutions/FA
 6/06/23  Biolase, Inc.                     8-K:3,5,8,9 6/05/23   12:225K                                   Donnelley … Solutions/FA
 5/26/23  Biolase, Inc.                     8-K:1,3,5,8 5/24/23   16:890K                                   Donnelley … Solutions/FA
 3/28/23  Biolase, Inc.                     10-K       12/31/22   90:19M                                    Donnelley … Solutions/FA
 1/05/23  Biolase, Inc.                     8-K:1,9    12/30/22   11:1.3M                                   Donnelley … Solutions/FA
11/10/22  Biolase, Inc.                     10-Q        9/30/22   83:14M                                    Donnelley … Solutions/FA
 6/08/22  Biolase, Inc.                     8-K:3,5,7,9 6/08/22   12:10M                                    Donnelley … Solutions/FA
 5/02/22  Biolase, Inc.                     8-K:5,9     4/28/22   11:180K                                   Donnelley … Solutions/FA
 3/03/22  Biolase, Inc.                     8-K:3,5,7,9 3/01/22   13:359K                                   Donnelley … Solutions/FA
 3/03/22  Biolase, Inc.                     8-A12G                 2:46K                                    Donnelley … Solutions/FA
11/10/21  Biolase, Inc.                     10-Q        9/30/21   84:13M                                    Donnelley … Solutions/FA
 4/19/21  Biolase, Inc.                     DEF 14A     5/26/21    1:1.2M                                   Donnelley … Solutions/FA
 6/01/20  Biolase, Inc.                     8-K:5,9     5/28/20    2:26K                                    Donnelley … Solutions/FA
 5/08/20  Biolase, Inc.                     10-Q        3/31/20   86:8.5M                                   ActiveDisclosure/FA
 4/23/20  Biolase, Inc.                     DEF 14A     5/13/20    1:1.5M                                   ActiveDisclosure/FA
 3/30/20  Biolase, Inc.                     10-K       12/31/19   90:24M                                    ActiveDisclosure/FA
 9/05/19  Biolase, Inc.                     S-1         9/04/19    3:929K                                   Donnelley … Solutions/FA
 4/10/19  Biolase, Inc.                     DEF 14A     5/15/19    1:971K                                   Donnelley … Solutions/FA
11/14/18  Biolase, Inc.                     10-Q        9/30/18   81:11M                                    ActiveDisclosure/FA
 8/24/18  Biolase, Inc.                     DEF 14A     9/21/18    1:1.6M                                   Donnelley … Solutions/FA
 5/11/18  Biolase, Inc.                     8-K:5,9     5/10/18    2:26K                                    Donnelley … Solutions/FA
 4/05/18  Biolase, Inc.                     DEF 14A     5/09/18    1:717K                                   Donnelley … Solutions/FA
10/03/17  Biolase, Inc.                     8-K:5,7,8,9 9/30/17    4:90K                                    Donnelley Fi… Express/FA
 7/21/17  Biolase, Inc.                     S-3                    4:281K                                   ActiveDisclosure/FA
 4/07/16  Biolase, Inc.                     DEF 14A     5/06/16    1:1M                                     Donnelley … Solutions/FA
11/06/15  Biolase, Inc.                     10-Q        9/30/15   68:7.2M                                   ActiveDisclosure/FA
11/04/14  Biolase, Inc.                     8-A12B/A               3:38K                                    Donnelley … Solutions/FA
 5/16/12  Biolase, Inc.                     8-K:5,7,9   5/10/12    3:44K                                    Donnelley Fi… Express/FA
12/23/05  Biolase, Inc.                     S-1/A                  6:2.3M                                   Donnelley … Solutions/FA
11/09/05  Biolase, Inc.                     10-Q        9/30/05    9:771K                                   Donnelley … Solutions/FA
 7/19/05  Biolase, Inc.                     10-K       12/31/04   17:2.2M                                   Donnelley … Solutions/FA
 6/03/02  Biolase, Inc.                     S-3                    6:225K                                   Donnelley R R & S… 11/FA
Top
Filing Submission 0001193125-24-019898   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 10, 2:53:09.4am ET